2011 - ISBTS 2011 Symposium


Plenary Session I: Disappearing PNLD? + Oral Communications 1

3.101 - Ninety-seven percent survivability, ninety-seven percent resolution of cholestasis at the Intestinal Rehabilitation Program (IRP) - Children’s National Medical Center (CNMC) Washington DC

Presenter: Clarivet, Torres, Washington, United States
Authors: Clarivet Torres1, Anthony Sandler1, Sona Sehgal1, Artis Krystal1, Pennigton Roshnee1, Carola Cerezo1, Stephanie Cahill1, Parvathi Mohan1


101
Ninety-seven percent survivability, ninety-seven percent resolution of cholestasis at the Intestinal Rehabilitation Program (IRP) - Children’s National Medical Center (CNMC) Washington DC

Clarivet Torres, Anthony Sandler, Sona Sehgal, Artis Krystal, Pennigton Roshnee, Carola Cerezo, Stephanie Cahill, Parvathi Mohan

Intestinal Rehabilitation Program, Children's National Medical Center, Washington, DC, United States

The treatment of intestinal failure is long-term parenteral nutrition (PN), intestinal rehabilitation or transplantation.  PN complications can lead to mortality in up to 50% of pediatric patients. Recent studies suggest that soybean-intralipids (SBIL) contribute to the development of hepatotoxicity, while the Omega 3 fatty acids (Omegaven) may reverse liver disease.  

We analyzed the outcomes of IF-PN-dependent patients treated over four years in the Intestinal Rehabilitation Program at Children’s National Medical Center, Washington-DC.

Seventy-three IF-PN dependent patients, who were on SBIL,were enrolled. Sixty-five had short bowel syndrome. The median age was 6mo. and forty were male. Median intestinal length was 33.5 cm. Median caloric requirements by PN at the time of enrollment were 100%. Thirty-seven had hyperbilirrubinemia, (Mean direct bilirubin of 10.5 mg/dl). Seventeen had liver biopsy (9 had portal fibrosis, 3 bridging, 3 cirrhosis). Height, weight Z score, platelet, albumin, bilirubin were obtained at the beginning and end of the study..

Thirty-six out of 37 patients (97%) with hyperbilirubinemia normalized their bilirubin. Mean time to normalize bilirubin was 10 weeks. Thirty reversed cholestasis while receiving PN (81%). Among the seventy-three patients, twenty had 24 lengthening procedures (9-Bianchi). Six were listed for intestinal transplant. Two are inactive and had resolved their cholestasis. Three were transplanted. Two died (one on the waiting list, one post-transplant). Of the sixty-eight remaining patients, 50 (73.5%) weaned off PN.  All laboratory parameters showed improvement (p< 0.0001). Overall Survival was 97%.

Patients with intestinal-failure treated in our institution reverse their cholestasis with the use of traditional SBIL in a shorter time and effectively, in contrast to the outcome in recent reports with the use of Omegaven. With meticulous medical/surgical management, patients with advanced liver disease can show improvement in liver functions and nutritional parameters with the ability to discontinue PN and avoid need for transplantation.

 

 

 

 


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi